Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 52 min 44 sec ago

Impulse Dynamics Completes $30 Million Financing Round

Fri, 05/13/2016 - 16:30
MT. LAUREL, New Jersey, May 13, 2016 -- (Healthcare Sales & Marketing Network) -- Impulse Dynamics, developer of the Optimizer™ IVs implantable device for treatment of chronic heart failure (CHF), announced today that the company has closed a $30 million ...
Devices, Cardiology, Venture Capital
Impulse Dynamics, Optimizer, heart failure

STAAR Surgical Announces Approval By Health Canada of Its EVO Visian ICL(TM) for Surgeons and Their Patients in Canada

Fri, 05/13/2016 - 13:51
MONROVIA, Calif., May 13, 2016 -- (Healthcare Sales & Marketing Network) -- STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, was notified yesterday of the appro...
Devices, Ophthalmology, Regulatory
STAAR Surgical, EVO Visian ICL, Collamer Lens

Boston Scientific Announces Schedule of Presentations at EuroPCR 2016

Fri, 05/13/2016 - 13:42
MARLBOROUGH, Mass., May 13, 2016 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (BSX) today announced the schedule of key data that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patie...
Devices, Interventional, Cardiology
Boston Scientific, EuroPCR, WATCHMAN, Lotus, SYNERGY

WaferGen Bio-systems and Takara Bio Inc. Announce Merger Agreement

Fri, 05/13/2016 - 13:35
Transaction scheduled to close following completion of the 2016 fiscal year FREMONT, Calif. and MOUNTAIN VIEW, Calif., May 13, 2016 -- (Healthcare Sales & Marketing Network) -- WaferGen Bio-systems, Inc. (WGBS), a publicly held genomics technology comp...
Diagnostics, Mergers & Acquisitions
WaferGen Bio-systems, Takara Bio USA Holdings

Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B

Fri, 05/13/2016 - 13:29
First Fc Fusion therapy approved for haemophilia B in the EU to provide extended protection against bleeds STOCKHOLM--(Healthcare Sales & Marketing Network)--Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (SOBI.ST) and Biogen (http://...
Biopharmaceuticals, Regulatory
Swedish Orphan Biovitrum, Sobi, Biogen, Alprolix, haemophilia B, hemophilia B

Cardiome Announces the Launch of ESMOCARD Solution for Injection in France

Thu, 05/12/2016 - 13:57
VANCOUVER, May 12, 2016 -- (Healthcare Sales & Marketing Network) - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that ESMOCARD® (esmolol hydrochloride) 100mg/10ml solution for injection has been commercialized by its subsidiary and ...
Biopharmaceuticals, Cardiology, Product Launch
Cardiome Pharma, OP Orphan Pharma, ESMOCARD

Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease

Thu, 05/12/2016 - 13:51
Top-Line Data Expected in December 2016 BOULDER, Colo., May 12, 2016 -- (Healthcare Sales & Marketing Network) -- Accera, Inc. today announced that it has completed enrollment of the NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of mil...
Biopharmaceuticals, Neurology
Accera , NOURISH AD, Alzheimer's disease

Mylan Launches Generic Frova(R) Tablets

Thu, 05/12/2016 - 13:44
HERTFORDSHIRE, England and PITTSBURGH, May 12, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova® Tablets. Mylan...
Biopharmaceuticals, Generics, Product Launch
Mylan, Frovatriptan, Frova , migraine

FDA Clears Next-Generation Version of EndoGastric Solutions’ EsophyX(R) Device

Thu, 05/12/2016 - 13:38
EsophyX® Z Fastener Delivery System requires fewer steps for Transoral Incisionless Fundoplication (TIF) procedures REDMOND, Wash.--(Healthcare Sales & Marketing Network)--EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy...
Devices, Gastroenterology, FDA
EndoGastric Solutions, EsophyX Z, SerosaFuse, GERD

Corvia Medical Announces CE Mark Approval And Enrollment Of First Patients In Randomized Clinical Study

Thu, 05/12/2016 - 13:28
Results from REDUCE LAP-HF TRIAL published in The Lancet TEWKSBURY, Mass., May 12, 2016 -- (Healthcare Sales & Marketing Network) -- Corvia Medical, Inc., a privately-held medical device company that has developed a first-in-class structural heart devi...
Devices, Interventional, Cardiology, Regulatory
Corvia Medical, InterAtrial Shunt Device, heart failure, Corvia Atrial

Hologic Introduces the MyoSure(R) REACH Device to Help Physicians Access the Hard-to-Reach Upper Third of the Uterine Cavity

Wed, 05/11/2016 - 23:23
Company Also Will Feature Full Range of Women's Health Topics at 2016 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting MARLBOROUGH, Mass., May 11, 2016 -- (Healthcare Sales & Marketing Network) -- Hologi...
Devices, Product Launch
Hologic, MyoSure, uterine fibroid

Hologic Introduces the MyoSure(R) REACH Device to Help Physicians Access the Hard-to-Reach Upper Third of the Uterine Cavity

Wed, 05/11/2016 - 15:22
Company Also Will Feature Full Range of Women's Health Topics at 2016 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting MARLBOROUGH, Mass., May 11, 2016 -- (Healthcare Sales & Marketing Network) -- Hologi...
Devices, Product Launch
Hologic, MyoSure, uterine fibroid

Medicure Files Application for New AGGRASTAT(R) Product Format

Wed, 05/11/2016 - 15:18
Expects to Launch Bolus Vial in Q3 2016 WINNIPEG, May 11, 2016 -- (Healthcare Sales & Marketing Network) - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce...
Biopharmaceuticals, Cardiology, FDA
Medicure, AGGRASTAT, tirofiban

Pernix Therapeutics Announces CEO Transition

Wed, 05/11/2016 - 15:16
Director John Sedor Appointed Interim CEO and Chairman MORRISTOWN, N.J., May 11, 2016 -- (Healthcare Sales & Marketing Network) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after di...
Biopharmaceuticals, Personnel
Pernix Therapeutics

Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate

Wed, 05/11/2016 - 15:13
SAN DIEGO, May 11, 2016 -- (Healthcare Sales & Marketing Network) -- Regen BioPharma, Inc., (RGBP), (RGBP) and (RGBPP) announced today that potential market expansion of its HemaXellerate therapy for aplastic anemia is a strategic priority. The Compan...
Biopharmaceuticals, Regenerative Medicine
Regen BioPharma, HemaXellerate, aplastic anemia

Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development

Wed, 05/11/2016 - 15:10
Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs ROCKVILLE, Md., May 11, 2016 -- (Healthcare Sales & Marketing Network) -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on ...
Biopharmaceuticals, Gastroenterology, Personnel
Synthetic Biologics, gut microbiome, irritable bowel syndrome

Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development

Tue, 05/10/2016 - 15:41
THE WOODLANDS, Texas, May 10, 2016 -- (Healthcare Sales & Marketing Network) -- Lexicon Pharmaceuticals, Inc. (LXRX), today announced that Praveen Tyle, Ph.D. will join the company as its executive vice president of research and development, effective May...
Biopharmaceuticals, Personnel
Lexicon Pharmaceuticals, Genome5000

Alexza Pharmaceuticals to be Acquired by Ferrer

Tue, 05/10/2016 - 15:37
MOUNTAIN VIEW, Calif. and BARCELONA, Spain, May 10, 2016 -- (Healthcare Sales & Marketing Network) -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza") and Grupo Ferrer Internacional, S.A. ("Ferrer") today announced that they have ...
Biopharmaceuticals, Mergers & Acquisitions
Alexza Pharmaceuticals, Grupo Ferrer Internacional, ADASUVE

Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders

Tue, 05/10/2016 - 15:34
EVANSTON, Ill., May 10, 2016 -- (Healthcare Sales & Marketing Network) -- Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurological disorders, today anno...
Biopharmaceuticals, Neurology, Venture Capital, Personnel
Aptinyx, N-methyl-D-aspartate

Medicure Announces Departure of President and Chief Operating Officer

Tue, 05/10/2016 - 15:32
WINNIPEG, May 9, 2016 -- (Healthcare Sales & Marketing Network) - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company today announced that the employment agreement with President and Chief Operating Officer, Daws...
Biopharmaceuticals, Cardiology, Personnel
Medicure, AGGRASTAT, tirofiban

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong